Skip to NavigationSkip to content

FDA approves Glenmark's generic version of Novartis' Exjade tablets for chronic iron overload

Published on 07/01/20 at 12:55pm

Indian pharma firm Glenmark has announced it has secured approval from the FDA for its oral deferasirox tablets in the treatment of high iron levels in the body as a result of multiple blood infusions.

The therapy is a generic version of Novartis’ Exjade iron chelator tablets used in the treatment of chronic iron overload, a condition which can eventually lead to organ damage and potentially serious conditions such as heart disease and diabetes. In the 12 months ending in November last year, the therapy generated $106.4 million in sales for Novartis.

The approval covers the Mumbai-based firm’s 125mg, 250mg and 500mg tablet formulations. Glenmark’s share price elevated by around 1.37% with the reveal of the news.

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches